Iron replacement in hemodialysis patients with a normal ferritin level;Eisensubstitution bei hämodiaiysepatienten mit normalem serumferritinspiegel

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 36, 2004, Pages 1849-1853

  Riedel, M K ^a   Morgenstern, T ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b Westpfalz Klinikum GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FERRIC GLUCONATE; FERRITIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN; FERRIC ION; HEMOGLOBIN;

ANEMIA; ARTICLE; CLINICAL ARTICLE; FERRITIN BLOOD LEVEL; HEALTH SURVEY; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; TRANSFERRIN BLOOD LEVEL; AGED; BLOOD; CHRONIC KIDNEY FAILURE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY ANEMIA; MALE; METABOLISM; MIDDLE AGED; RENAL REPLACEMENT THERAPY; SUBCUTANEOUS DRUG ADMINISTRATION; TIME; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; ERYTHROPOIETIN, RECOMBINANT; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; IRON; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; RENAL DIALYSIS; TIME FACTORS; TRANSFERRIN; TREATMENT OUTCOME;

EID: 4544380874     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-831347     Document Type: Article

References (27)

1. Chuang CL et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant 2003; 18: 370-377
2. Dale JC et al. Diurnal variation of serum iron, iron-binding capacity, transferrin saturation, and ferritin levels. Am J Clin Pathol 2002; 117: 802-808
3. Edwards CQ et al. Prevalence of hemochromatosis among 11,065 presumably healthy blood donors. N Engl J Med 1988; 318: 1355-1362
4. European best practice guidelines for the management of anemia in patients with chronic renal failure. Nephrol Dial Transplant 1999; 14(Suppl 5); 14-18
5. Fishbane S, Kowalski EA, Imbriano LJ, Maesaka JK. The evaluation of iron status in hemodialysis patients.J Am Soc Nephrol 1996; 7: 2654-2657
6. Hamilton LD, Gubler CH, Cartwright GE, Wintrobe MM. Diurnal variation in the plasma iron level of man. Proc Soc Exp Biol 1950; 75: 65-68
7. Heimpel H, Riedel M, Wennauer R, Thomas L. Die Serumeisenbestimmung - nützlich, unnötig oder irreführend? Med Klin 2003; 98: 104-107
8. Kalantar-Zadeh K et al. Diagnosis of iron deficiency anemia in renal failure patients during the post-erythropoietin era. Am J Kidney Dis 1995; 26: 292-299
9. Kalantar-Zadeh K, Kleiner M, Dunne E et al. Total iron-binding capacity-estimated transferrin correlates with the nutritional subjective global assessment in hemodialysis patients. Am J Kidney Dis 1998; 31: 263-272
10. Kaltwasser JP, Gottschalk R. Erythropoietin and iron. Kidney Int 1999; 55 (Suppl 69); S49-S55
11. Kaufman JS, Reda DJ, Fye CL et al. Diagnostic value of iron indices in hemodialysis patients receiving epoetin. Kidney Int 2001; 60: 300-308
12. Macdougall IC, Cavill I, Hulme B et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. BMJ 1992; 304: 225-226
13. Macdougall IC et al. Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical algorithm. BMJ 1990; 300: 655-659
14. Macdougall IC et al. A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996; 50: 1694-1699
15. Niederau C, Niederau CM, Lange S et al. Screening for hemochromatosis and iron deficiency in employees and primary care patients in Western Germany. Ann Intern Med 1998; 128: 337-345
16. Niederau C. Heriditäre Hämochromatose. Internist 2003; 44: 191-205
17. Nissenson AR. Hyporesponsiveness to erythropoietin: overview, 1996. Perit Dial Int 1996; 16: 417-420
18. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease: update 2000. Am J Kidney Dis 2001; 37 (Suppl 1); S182-S238
19. Paterson JCS, Marrack D, Wiggins HS. The diurnal variation of serum iron level in erythropoietic disorders. J Clin Pathol 1953; 6: 105-109
20. Schaefer RM, Schaefer L. The hypochromic red cell: a new parameter for monitoring of iron supplementation during rhEPO therapy. J Perinat Med 1995; 23: 83-88
21. Silverberg DS, laina A, Peer G et al. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis. Am J Kidney Dis 1996; 27: 234-238
22. Tarng DC, Huang TP. Hyporesponsiveness to erythropoietin. Perit Dial Int 1997; 17: 99-100
23. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423
24. Van Wyck DB et al. Iron status in patients receiving erythropoietin for dialysis-associated anemia. Kidney Int 1989; 35: 712-716
25. Werner M. Serum protein changes during the acute phase reaction. Clin Chim Acta 1969; 25: 299-305
26. Wingard RL et al. Efficacy of oral iron therapy in patients receiving recombinant human erythropoietin. Am J Kidney Dis 1995; 25: 433-439
27. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, de Jong GM. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 820-824